Want to see AU:SIG full AI Analyst Report?
Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Select Model
Select Model
Rating:61Neutral
Price Target:
AU$3.00
▲(7.14% Upside)
Action:Reiterated
Date:08/28/26
The score is primarily supported by improved recent financial performance (higher revenue scale, better margins, and positive free cash flow), but is held back by weak technicals (price below major moving averages with negative MACD) and a relatively expensive valuation (high P/E with only a modest dividend yield).
Positive Factors
Scale and Margin Expansion
The sharp increase in revenue and profitability indicates stronger operating scale and improved economics in pharmaceutical distribution. If sustained, the larger earnings base can support reinvestment, strengthen supplier and pharmacy relationships, and improve resilience.
Negative Factors
Volatile Earnings History
The latest improvement has not yet established a consistently proven earnings track record. Earlier losses and thin margins indicate that profitability may remain sensitive to distribution economics, operating execution and changes in pharmacy-sector conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale and Margin Expansion
The sharp increase in revenue and profitability indicates stronger operating scale and improved economics in pharmaceutical distribution. If sustained, the larger earnings base can support reinvestment, strengthen supplier and pharmacy relationships, and improve resilience.
Read all positive factors
Sigma Healthcare Ltd (SIG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$31.12B
Dividend Yield0.74%
Average Volume (3M)15.27M
Price to Earnings (P/E)43.8
Beta (1Y)0.40
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.06
Shares Outstanding11,543,703,000
10 Day Avg. Volume19,634,037
30 Day Avg. Volume15,267,475
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)6.33
Price to Sales (P/S)2.92
P/FCF Ratio60.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.17Price Target Upside13.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$12.08B
Sigma Healthcare Ltd Business Overview & Revenue Model
Company Description
Sigma Healthcare Limited, together with its various operating divisions, primarily engages in the wholesale supply and distribution of pharmaceutical goods across Australia. The company also manages a significant network of approximately 1,200 ret...
How the Company Makes Money
Sigma Healthcare makes money primarily through pharmaceutical wholesaling and distribution. Its core revenue stream is the sale and delivery of medicines and pharmacy products to pharmacies and other customers, earning a gross margin on products s...
Sigma Healthcare Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.83B | 10.83B | 4.89B | 3.32B | 3.66B | 3.45B |
| Gross Profit | 1.96B | 1.96B | 334.05M | 189.82M | 224.07M | 199.42M |
| EBITDA | 1.08B | 1.08B | 55.47M | 53.25M | 50.20M | 30.23M |
| Net Income | 709.18M | 709.18M | -13.84M | 4.51M | 1.81M | -7.24M |
Balance Sheet | ||||||
| Total Assets | 9.34B | 9.34B | 1.83B | 1.40B | 1.20B | 1.28B |
| Cash, Cash Equivalents and Short-Term Investments | 131.12M | 131.12M | 14.57M | 356.50M | 16.65M | 31.14M |
| Total Debt | 2.02B | 2.02B | 132.09M | 136.63M | 226.99M | 323.43M |
| Total Liabilities | 4.35B | 4.35B | 991.29M | 531.52M | 723.84M | 786.65M |
| Stockholders Equity | 5.00B | 5.00B | 837.86M | 870.77M | 475.92M | 487.19M |
Cash Flow | ||||||
| Free Cash Flow | 518.83M | 518.83M | -323.50M | 37.25M | 113.34M | -60.48M |
| Operating Cash Flow | 575.56M | 575.56M | -315.59M | 41.97M | 142.74M | -46.28M |
| Investing Cash Flow | 61.69M | 61.69M | -1.60M | 5.73M | -28.60M | -16.59M |
| Financing Cash Flow | -645.19M | -645.19M | -24.73M | 295.82M | -116.94M | 128.89M |
Sigma Healthcare Ltd Technical Analysis
Negative
2.80
Price Trends
2.87
Negative
2.85
Negative
2.85
Negative
Market Momentum
-0.05
Positive
33.34
Neutral
30.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SIG, the sentiment is Negative. The current price of 2.8 is below the 20-day moving average (MA) of 2.88, below the 50-day MA of 2.87, and below the 200-day MA of 2.85, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 33.34 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SIG.
Sigma Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$807.06M | 45.93 | 8.16% | ― | 2.59% | -13.36% | |
61 Neutral | AU$31.12B | 43.83 | 14.34% | 0.44% | ― | ― | |
58 Neutral | AU$82.52B | -23.65 | -15.12% | 3.68% | -2.49% | -179.79% | |
57 Neutral | AU$264.51M | 10.06 | 6.58% | ― | -5.98% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$231.74M | -14.58 | -5.34% | ― | 1.84% | -178.23% | |
39 Underperform | AU$18.68M | -5.07 | 4388.00% | ― | -19.29% | 62.42% |
* Healthcare Sector Average
AU:SIG
Sigma Healthcare Ltd
2.71
-0.36
-11.64%
AU:MYX
Mayne Pharma Group
3.12
-2.15
-40.80%
AU:CSL
CSL
173.85
-28.58
-14.12%
AU:NAN
Nanosonics Limited
2.69
-1.46
-35.18%
AU:PGC
Paragon Care Limited
0.14
-0.19
-57.58%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-36.36%
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare sets post-merger governance framework after Chemist Warehouse deal
Aug 27, 2026
Sigma Healthcare Limited, a major Australian pharmacy franchisor and pharmaceutical wholesaler, has detailed its governance framework for the merged entity created following its 2025 combination with Chemist Warehouse. The company underscores its ...
Sigma Healthcare Declares Interim Dividend for Half-Year to June 2026
Aug 27, 2026
Sigma Healthcare Ltd has declared a fully paid ordinary share dividend of AUD 0.02 for the six-month period ended 30 June 2026, reinforcing returns to shareholders through a scheduled cash distribution. The dividend will trade ex on 3 September 20...
Sigma Healthcare Files 2026 Corporate Governance Appendix 4G
Aug 27, 2026
Sigma Healthcare Limited has lodged its Appendix 4G for the financial year ended 30 June 2026, outlining how it complies with ASX Corporate Governance Council principles. The company’s corporate governance statement, current as at 26 August ...
Sigma Healthcare posts strong FY26 growth as Chemist Warehouse merger fuels earnings and global expansion
Aug 26, 2026
Sigma Healthcare reported FY26 revenue of $10.8 billion and Normalised EBIT of $1.09 billion, representing 15.5% and 20.6% growth respectively, as its first full year post-merger with Chemist Warehouse delivered strong operating leverage. Normalis...
Sigma Healthcare-Chemist Warehouse Merger Delivers Strong First Full-Year Results
Aug 26, 2026
Sigma Healthcare Limited operates as a major pharmacy wholesaler and retail healthcare group in Australia, with its merged operations now anchored around the Chemist Warehouse network. The company focuses on pharmaceutical distribution, retail pha...
Sigma Healthcare sets 2026 AGM date and director nomination deadline
Aug 25, 2026
Sigma Healthcare has scheduled its 2026 Annual General Meeting for 2.00 pm AEDT on Wednesday 21 October 2026, with detailed information to be provided to shareholders in a Notice of Meeting in September. The company has also opened the process for...
Sigma Healthcare to unveil FY26 results with new segment reporting and normalised earnings
Aug 13, 2026
Sigma Healthcare will release its FY26 full-year results for the period ending 30 June 2026 to the ASX on 27 August, accompanied by a webcast briefing with a live QA and later access to a recording and transcript for investors who cannot attend. T...
Sigma Healthcare to Release Over 5 Billion Escrowed Shares Held by Chemist Warehouse Founders
Jul 9, 2026
Sigma Healthcare will release 5,023,079,098 fully paid ordinary shares from voluntary escrow at the close of trading on 27 August 2026, coinciding with the announcement of its financial results for the period ending 30 June 2026. These shares are ...
Sigma Healthcare Sets Date for FY26 Results and Investor Webcast
Jul 2, 2026
Sigma Healthcare has advised that it will publish its full year results for the 12 months to 30 June 2026 on the morning of 27 August 2026, giving investors a clear timetable for the release of key financial and operational information. Following ...
Sigma Confirms Exploratory Talks in Boots Sale Process
Jun 9, 2026
Sigma Healthcare has addressed recent media reports linking it to the sale process of UK-based pharmacy chain The Boots Group, confirming it has held preliminary discussions. The company stated that these talks are part of its ongoing review of op...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.